Clinical Trial – Friday Pop Quiz 6/5
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and …
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and … 
This patient presents for Mohs surgery. What is the deepest layer that you can undermine in this area?
A. Epidermis
B. Dermis
C. Subcutaneous fat
D. Superficial muscular aponeurotic system (SMAS)
E. Muscle
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
What is the most common cause of hypertension in this patient?
A. Autonomic Dysregulation
B. Optic Glioma
C. Renal Artery Stenosis
D. Medication induced
E. Medullary adrenal gland tumor
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
What are the nail findings in this condition?
A. Red-white longitudinal bands and v-shaped distal nicks
B. Oil spots and onycholysis
C. Clubbing
D. Dolichonychia
E. Trachyonychia
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
Here are the issue highlights and editor picks for JDD's May issue:
Broad area ALA may be beneficial for prevention of new or recurrent lesion formation in patients at high risk for AK and NMSC in A Randomized Trial of Broad Area ALA–PDT for Field Cancerization Mitigation in High-Risk Patients.
Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Tre … 